Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B036 in Locally Advanced or Metastatic Solid Tumors
NCT07606612Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-B036 in solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
SI-B036
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07606612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606612.